Neurocritical Care

, 10:141

Metaanalysis of Tirilazad Mesylate in Patients with Aneurysmal Subarachnoid Hemorrhage

  • Yeon Gyoe Jang
  • Don Ilodigwe
  • R. Loch Macdonald
Review

DOI: 10.1007/s12028-008-9147-y

Cite this article as:
Jang, Y.G., Ilodigwe, D. & Macdonald, R.L. Neurocrit Care (2009) 10: 141. doi:10.1007/s12028-008-9147-y

Abstract

Background

Tirilazad is a non-glucocorticoid, 21-aminosteriod that inhibits lipid peroxidation. It had neuroprotective effects in experimental ischemic stroke and reduced angiographic vasospasm after experimental subarachnoid hemorrhage (SAH). Five randomized clinical trials of tirilazad were conducted in patients with SAH. We performed a meta-analysis of these trials to assess the effect of tirilazad on unfavorable outcome, symptomatic vasospasm, and cerebral infarction after SAH.

Methods

Data from 3,797 patients were analyzed and modeled using random effect and Mantel-Haenszel meta-analyses and multivariable logistic regression to determine the effect of tirilazad on clinical outcome, symptomatic vasospasm, and cerebral infarction. Clinical outcome was assessed 3 months after SAH using the Glasgow outcome scale, and symptomatic vasospasm was defined by clinical criteria with laboratory and radiological exclusion of other causes of neurological deterioration.

Results

The five trials were randomized, double-blind, and placebo-controlled. Tirilazad did not significantly decrease unfavorable clinical outcome on the GOS (odds ratio [OR] 1.04, 95% confidence interval [CI] 0.89–1.20) or cerebral infarction (OR 1.04, 95% CI 0.89–1.22). There was a significant reduction in symptomatic vasospasm in patients treated with tirilazad (OR 0.80, 95% CI 0.69–0.93). There was no heterogeneity across the five trials.

Conclusion

Tirilazad had no effect on clinical outcome but did decrease symptomatic vasospasm in five trials of aneurysmal SAH. The dissociation between clinical outcome and symptomatic vasospasm deserves further investigation.

Keywords

Cerebral vasospasmMeta-analysisSubarachnoid hemorrhageTirilazad

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Yeon Gyoe Jang
    • 1
  • Don Ilodigwe
    • 1
  • R. Loch Macdonald
    • 1
    • 2
  1. 1.Division of Neurosurgery, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s HospitalUniversity of TorontoTorontoCanada
  2. 2.Department of SurgeryUniversity of TorontoTorontoCanada